Prevalence of and viral outcomes associated with primary HIV-1 drug resistance

Open AIDS Journal

Volumn 6, Issue SPEC.ISSUE 1, 2012, Pages 181-187

  Buskin, S E ^a,b   Zhang, S ^a   Thibault, C S ^a  

^a PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

HIV drug resistance surveillance; HIV transmitted drug resistance; HIV viral load; HIV 1

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AMERICAN INDIAN; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; DEMOGRAPHY; DISEASE SURVEILLANCE; DRUG CLASSIFICATION; FEMALE; GENOTYPE; HEALTH CARE DISPARITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAVENOUS DRUG ABUSE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MULTIDRUG RESISTANCE; NEGRO; OUTCOME ASSESSMENT; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEX DIFFERENCE; TREND STUDY; UNITED STATES; VIRUS LOAD; VIRUS MUTATION;

EID: 84871010618     PISSN: None     EISSN: 18746136     Source Type: Journal    
DOI: 10.2174/1874613601206010181     Document Type: Article

References (29)

1. Buchacz K, Baker RK, Palella FJ Jr, et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010; 24(10): 1549-59.
2. Ray M, Logan R, Sterne JA, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24(1): 123-37.
3. Booth C. Transmitted resistance. In: Geretti AM, ed Antiretroviral Resistance in Clinical Practice NCBI Bookshelf A service of the National Library of Medicine, National Institutes of Health London 2006.
4. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010; 24(8): 1203-12.
5. Delaugerre C, Morand-Joubert L, Chaix ML, et al. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther 2004; 9(3): 415-21.
6. Leigh Brown AJ, Frost SD, Mathews WC, et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003; 187(4): 683-6.
7. Pao D, Andrady U, Clarke J, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37(5): 1570-3.
8. Bhaskaran K, Pillay D, Walker AS, et al. Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters. AIDS 2004; 18(10): 1471-3.
9. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288(2): 181-8.
10. Little SJ, Frost SD, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008; 82(11): 5510-8.
11. Menzo S, Monachetti A, Balotta C, et al. Processivity and drugdependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. AIDS 2003; 17(5): 663-71.
12. Pillay D, Bhaskaran K, Jurriaans S, et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006; 20(1): 21-8.
13. Zaccarelli M, Tozzi V, Perno CF, Antinori A. The challenge of antiretroviral-drug-resistant HIV: is there any possible clinical advantage? Curr HIV Res 2004; 2(3): 283-92.
14. Zaccarelli M, Tozzi V, Lorenzini P, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005; 19(10): 1081-9.
15. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. pp. 1-166. Oct 1, 2011.
16. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5(6): e11068.
17. Markovitz AR, Thibault CS, Brandauer PW, Buskin SE. Primary antiretroviral drug resistance in newly human immunodeficiency virus-diagnosed individuals testing anonymously and confidentially. Microb Drug Resist 2011; 17: 283-9.
18. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4(3): e4724.
19. Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 2006; 194(Suppl 1): S51-8.
20. Bracciale L, Colafigli M, Zazzi M, et al. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. J Antimicrob Chemother 2009; 64(3): 607-15.
21. Buchacz K, Baker RK, Young B, Brooks JT. Changes in the use of HIV antiretroviral resistance testing in a large cohort of U.S. patients, 1999 to 2006. J Acquir Immune Defic Syndr 2010; 53(5): 625-32.
22. Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM. Antiretroviral drug resistance in HIV-1-infected patients with lowlevel viremia. J Infect Dis 2010; 201(9): 1303-07.
23. Russell JS, Chibo D, Kaye MB, et al. Prevalence of transmitted HIV drug resistance since the availability of highly active antiretroviral therapy. Commun Dis Intell 2009; 33(2): 216-20.
24. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288(2): 181-8.
25. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347(6): 385-94.
26. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353(9171): 2195-9. Erratum in: Lancet 1999; 354: 1128.
27. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16: 209-18.
28. Bannister WP, Cozzi-Lepri A, Clotet B, et al. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr 2008; 48: 324-33.
29. Wittkop L, Günthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363-71.